Deucravacitinib Production Cost Reports

The report provides a detailed analysis essential for establishing a deucravacitinib production plant. It encompasses all critical aspects necessary for deucravacitinib production, including the cost of deucravacitinib production, deucravacitinib plant cost, deucravacitinib production costs, and the overall deucravacitinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a deucravacitinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more. 

Deucravacitinib is a medication that is primarily used in the treatment of autoimmune diseases, particularly psoriasis. It is an oral Janus kinase (JAK) inhibitor that works by blocking specific enzymes responsible for the inflammation associated with these conditions. It is mainly used for the management of moderate to severe plaque psoriasis, which helps to reduce symptoms like redness, scaling, and itching. It is also being explored for other inflammatory conditions, such as rheumatoid arthritis, lupus, and inflammatory bowel disease, where it may help control immune system activity. It also serves as a convenient pill alternative to injections, which improves patient compliance in dermatology and rheumatology settings. Additionally, it is being studied for its potential in treating other immune-mediated disorders like palmoplantar pustulosis, as it provides targeted treatment with potentially fewer side effects compared to other immunosuppressive drugs.

The market for deucravacitinib is primarily driven by its application as a targeted oral medication for the treatment of certain immune-related conditions, which supports its demand in the medical sector. Its application in the treatment of patients with moderate to severe plaque psoriasis in adults who require systemic therapy also promotes its demand in the dermatology and pharmaceutical industries. Its involvement in managing other inflammatory conditions, such as lupus and psoriatic arthritis, and improving skin conditions further boosts its demand in the medical and healthcare sectors.

Its demand as a convenient treatment option in dermatology clinics for patients who have not responded well to topical treatment or other immunosuppressive drugs also drives its market growth. Additionally, procurement practices are influenced by factors such as the availability and cost of active pharmaceutical ingredients, strict regulatory approvals, patent protections, and quality compliance standards. Manufacturing capabilities, supply chain stability, technological expertise, and adherence to safety and environmental regulations also play a significant role in shaping industrial deucravacitinib procurement globally.

Raw Material for Deucravacitinib Production

According to the deucravacitinib production plant project report, the major raw materials for deucravacitinib production include pyridazine, aniline, and trideuterated methylamides.

Production Process of Deucravacitinib

The extensive deucravacitinib production cost report consists of the following industrial production process:

1. Production via Amide Coupling Reaction: The production process of deucravacitinib begins with a Lewis acid-mediated SNAr reaction between pyridazine and aniline, which forms a compound with excellent regioselectivity. This product is isolated as a stable Zn-dicarboxylate for easy handling. Further, the obtained Zn-dicarboxylate undergoes a Pd-catalysed C-N bond formation with amide to form the main intermediate carboxylate. Then, trideuterated methylamides are attached via standard amide coupling, followed by crystallisation from NMP and i-PrOH results in the formation of deucravacitinib as the final substance.

Deucravacitinib is a selective, allosteric inhibitor of tyrosine kinase 2 (TYK2) that appears as a white to yellow powder with no characteristic odour. The molecular formula of the compound is C20H22N8O3, where three hydrogen atoms in the methyl amide group are replaced by deuterium, and its molar mass is 425.47 g/mol. It is also known by its brand name Sotyktu. The solubility of the compound is pH-dependent, with solubility decreasing as the pH increases, which makes it more soluble in acidic conditions. It is available as a 6 mg oral tablet and is recommended to be stored at a controlled room temperature of 20 to 25 degree Celsius, with excursions permitted between 15 and 30 degree Celsius. It is a potent immunomodulatory agent, and it requires careful handling. Patients are advised to avoid receiving live vaccines during treatment, as it may increase susceptibility to infections. Prolonged use of this compound may be associated with adverse effects such as upper respiratory tract infections, acne, and folliculitis, and it is recommended to be used under strict medical supervision.